Cytoreductive Surgery

The term cytoreductive surgery refers to an operation aimed at reducing the amount of visible cancer in the body, often within the abdomen and pelvis. The exact organs or tissues involved depend on where the disease is located and what can be removed safely.

This is a treatment strategy rather than a single fixed procedure, which is why planning is highly individualized.

The purpose of cytoreductive surgery is to remove visible tumor deposits when that is considered feasible and medically appropriate.

What “removing visible tumour” means: at the end of the operation the surgeon records how much cancer was left:

• Complete — no visible cancer left (sometimes written CC-0 or R0). This is the aim, and it is linked to the best results.
• Optimal — only small deposits left, each under about 1 cm.
• Suboptimal — larger amounts left; chemotherapy then has more work to do.

The surgical goal is shaped by safety, disease extent, and the realistic likelihood of benefit, not by an assumption that more surgery is always better.

Cytoreductive surgery is most commonly discussed in ovarian, fallopian tube, and primary peritoneal cancers, especially when disease is present across peritoneal surfaces. There are two common timings:

• Primary (upfront) surgery — surgery first, followed by chemotherapy, when scans suggest all visible cancer can be removed and you are fit for a major operation.
• Interval surgery — a few cycles of chemotherapy first to shrink the cancer, then surgery, then more chemotherapy. This is used when the cancer is very widespread or you need time to get fitter.

Which order is right depends on scans, fitness and whether complete removal looks possible; candidacy depends on careful preoperative review rather than diagnosis alone.

Cytoreductive surgery and HIPEC are related but not identical. Cytoreductive surgery focuses on removing visible tumor, while HIPEC adds heated chemotherapy within the abdominal cavity during the operation in selected situations.

Some patients may be considered for cytoreductive surgery without HIPEC, while others may have both considered together. The decision depends on disease pattern, surgical findings, prior treatment, and specialist judgment.

Chemotherapy is part of almost every treatment plan for advanced ovarian cancer, and the order of surgery and chemotherapy is decided for each patient — read how chemotherapy fits into treatment.

Before surgery, the team reviews scans, pathology, general health, and surgical fitness. During the operation, the surgeon assesses the extent of disease and removes visible tumor from involved areas as safely as possible based on the preoperative plan and operative findings.

Patients do not need every technical detail in advance, but they should understand the goal of surgery, the possibility of a complex abdominal procedure, and how the operation fits into the broader treatment plan.

This is a major operation, often lasting several hours, and recovery takes time. As a general guide for advanced cancer-removal surgery:

• Hospital stay: about 10–14 days, including a few days in the ICU
• Back to gentle daily activity: about 4–6 weeks
• Full recovery: often 3–4 months

Recovery depends on the extent of surgery, baseline health, and whether additional treatment is planned afterward. Fatigue, reduced activity tolerance, and a gradual return to routine are common. Follow-up review helps the team assess healing, pathology findings, and the next step in treatment.

Cytoreductive surgery should be planned by a team that can assess surgical feasibility, cancer biology, imaging findings, and the likely role of other treatments such as chemotherapy or HIPEC. The best plan depends on the full clinical picture rather than on the procedure name alone.

Specialist-led planning helps patients understand whether surgery is being considered for meaningful treatment benefit and what the realistic expectations should be.